NCT06704997Active, not recruiting
Machine Learning to Predict Factors Affecting Rehabilitation Length of Stay and Healthcare Costs for Neurological Rehabilitation
Machine Learning Predictive Analysis of Key Factors Influencing Rehabilitation Length of Stay (RLOS) and Direct Hospitalization Costs for Neurological Inpatient Rehabilitation at Tertiary Care Hospital
Source: ClinicalTrials.gov · Last updated 7 Oct 2026
Brief summary (registry, in English)
The aim of this retrospective study is to ascertain total direct costs, rehabilitation length of stay (RLOS) and factors associated with RLOS for neurological inpatient rehabilitation at the tertiary care hospital.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 10000 (estimated)
- First submitted
- 22 Nov 2024
- Start date
- 1 Jun 2024
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- Tan Tock Seng Hospital
- Diseases
- Stroke
- NCT number
- NCT06704997
What you commit to
- Study type: Observational
- Planned participants: 10000
- From 1 Jun 2024 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Did not complete inpatient rehabilitation as they are discharged against medical advice
Who the study is looking for
- All patients who completed inpatient rehabilitation with the index conditions in their discharge summaries
Age in the registry: 21 years to 100 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Tan Tock Seng Hospital Coordinator of this site? Confirm its status | Singapore | Singapore | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.